Damora Therapeutics, Inc. (NASDAQ: DMRA) granted equity awards to six newly hired, non-executive employees on August 1, 2026, as material inducements for their acceptance of employment with the biotechnology company. The grants, approved by Damora’s independent Compensation Committee of its Board of Directors, comply with Nasdaq Listing Rule 5635(c)(4), which allows companies to issue equity to new hires without prior shareholder approval if specific criteria are met. This move supports Damora’s strategy to expand its team while advancing its pipeline of biologics for hematologic disorders.

The inducement grants consist of options to purchase an aggregate of 451,000 Damora ordinary shares. Each option carries a 10-year term and an exercise price of $28.99 per share. The vesting schedule requires that 25% of the options vest on the first anniversary of each employee’s start date, with the remaining balance vesting in equal monthly installments over the following 36 months.

Grant Details

The structure of the equity awards aligns with standard retention practices in the biotechnology sector, tying long-term compensation to continued employment. The grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan and individual option award agreements.

Strategic Context

Damora Therapeutics is focused on redefining care for patients with blood disorders, specifically advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms. These conditions include essential thrombocythemia and myelofibrosis, areas where there is significant medical need for disease-modifying treatments. The company aims to bring forward optimized therapies with broad mutation coverage and exceptional convenience to improve patient outcomes.

With multiple programs having best-in-class potential on track to enter clinical development in 2026, the addition of new talent through these inducement grants underscores Damora’s commitment to accelerating its research and development efforts. The equity incentives are designed to attract specialized expertise necessary for navigating the complex regulatory and scientific landscape of hematology drug development.

Damora Therapeutics, Inc. (Damora) has completed its redomestication from the State of Delaware to the Cayman Islands, effective July 16, 2026. The transition does not alter the company’s business, management, obligations, assets, or liabilities. Each outstanding share of the Delaware company’s common stock automatically converted into one ordinary share, with a par value of $0.00001 per share. Preferred stock shares similarly converted on a one-to-one basis for each corresponding series.

The redomestication was approved by Damora’s board of directors and subsequently by stockholders at a Special Meeting held on February 9, 2026. Effective July 20, 2026, the company’s ordinary shares will trade on Nasdaq under a new CUSIP number, G2646Y104. The trading symbol "DMRA" remains unchanged.

Share Conversion Details

Damora Therapeutics is a biotechnology company focused on developing biologics for hematologic disorders, including essential thrombocythemia and myelofibrosis. The company has multiple programs with best-in-class potential scheduled to enter clinical development in 2026.